US-headquartered Waters Corporation has announced the launch of OligoWorks™ SPE (solid phase extraction) kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realise up to a 2x increase over competing products in oligonucleotide recovery from biofluids.

The kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics, and 500+ in the pipeline. While potent, these highly modified oligonucleotides are challenging to precisely quantify during dosing, metabolism, and tissue distribution studies.

OligoWorks SPE Kits also use an innovative, enzyme-enhanced, and detergent-free sample pretreatment that reduces washing steps and improves mass spectrometer compatibility, thus enabling direct injection LC-MS analysis and lower limits of quantitation. They can also be fully automated for improved productivity, or to simply help scientists gain back time by reducing manual steps and oversight.